Pulmonary fibrosis: "idiopathic" is not "cryptogenic"
Eur Respir J
.
2019 Mar 18;53(3):1900400.
doi: 10.1183/13993003.00400-2019.
Print 2019 Mar.
Authors
Athol U Wells
1
,
Kevin K Brown
2
,
Kevin R Flaherty
3
,
Martin Kolb
4
,
Victor J Thannickal
5
;
IPF Consensus Working Group
;
IPF Consensus Working Group:
Collaborators
K M Antoniou
,
J Behr
,
P B Bitterman
,
C D Cool
,
U Costabel
,
T V Colby
,
V Cottin
,
B Crestani
,
G P Downey
,
J Gauldie
,
S D Groshong
,
A Guenther
,
J C Horowitz
,
Y Inoue
,
J A Lasky
,
A H Limper
,
D A Lynch
,
F J Martinez
,
J L Myers
,
A G Nicholson
,
I Noth
,
V Poletti
,
C J Ryerson
,
J H Ryu
,
D Valeyre
,
C Vancheri
,
E S White
Affiliations
1
Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
[email protected]
.
2
National Jewish Health, Denver, CO, USA.
3
University of Michigan Health System, Ann Arbor, MI, USA.
4
Dept of Respiratory Medicine, Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
5
Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
PMID:
30886028
DOI:
10.1183/13993003.00400-2019
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Lung
Pulmonary Fibrosis*
Grants and funding
R01 HL130796/HL/NHLBI NIH HHS/United States
R01 HL141195/HL/NHLBI NIH HHS/United States